S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
NGNE · Neurogene Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
$26.14
+0.74
(+2.89%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$26.14
$25.17
$26.85
52-WEEK RANGE
$26.14
$15.93
$43.66
What's happening
- NGNE is up 2.89% today, trading at $26.14. — Live quote
- Volume today (26,795) is well below its 3-month average of 277,110. (Finnhub fundamentals)
- Reports earnings on 2026-11-11 (before market open), 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-1.53 actual vs. $-1.45 estimated (-5.4%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 6
Buy 8
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (15 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
NGNE
+23.30%
vs S&P 500
+10.52%
1-YEAR RETURN
NGNE
-21.02%
vs S&P 500
-35.58%
6-MONTH RETURN
NGNE
-0.90%
3-MONTH RETURN
NGNE
-30.75%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-1.53
Est. $-1.45
MISS -5.4%
2026-04-26 (Q1 2026)
$-1.39
Est. $-1.32
MISS -5.1%
2026-01-26 (Q4 2025)
$-1.17
Est. $-1.21
BEAT +3.5%
2025-10-26 (Q3 2025)
$-0.99
Est. $-1.27
BEAT +22.4%
Valuation Measures & Ratios
Enterprise Value4$397.2M
Forward P/E5—
PEG Ratio6-0.23
Price / Sales (TTM1)551.02
Price / Book72.77
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-25.27%
Return on Assets (ROA9)-23.25%
Avg Volume (3M)277,110
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $706.1M | $450.0M | $368.1M | $314.4M | $246.8M |
| P/E | -6.51 | -4.66 | -4.29 | -3.77 | -3.15 |
| Price/Book | 3.25 | 1.89 | 1.39 | 1.15 | 0.85 |
| EV/EBITDA | -5.09 | -3.07 | -3.13 | — | — |
| ROE | -49.92% | -40.60% | -32.32% | -30.51% | -26.83% |
| ROA | -44.36% | -36.69% | -29.82% | -28.04% | -24.83% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short4,974,749
Change from Prior Settlement+51.66%
% of Float—
Days to Cover (Short Ratio)11.73
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-10-02; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -21.0%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on NGNE
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | — | $0 | $925.0K | — |
| Operating income | -$36.7M | -$33.3M | -$23.8M | -$26.1M | -$25.9M | -$22.2M | -$20.1M | -$18.8M |
| Net income | -$34.5M | -$30.9M | -$21.0M | -$22.0M | -$22.6M | -$20.2M | -$18.5M | -$16.9M |
| EPS (diluted) | $-1.53 | $-1.39 | $-0.99 | $-1.05 | $-1.08 | $-1.19 | $-1.09 | $-1.00 |
| EPS (basic) | $-1.53 | $-1.39 | $-0.99 | $-1.05 | $-1.08 | $-1.19 | $-1.09 | $-1.00 |
| Operating margin | — | — | — | — | — | — | -$2.2K | — |
| Net margin | — | — | — | — | — | — | -$2.0K | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $244.4M | $263.1M | $288.6M | $287.8M | $297.3M | $315.3M | $335.7M | $164.1M |
| Total liabilities | $27.2M | $25.4M | $23.7M | $22.3M | $24.1M | $23.5M | $25.4M | $26.7M |
| Stockholders' equity | $217.1M | $237.8M | $264.9M | $265.5M | $273.3M | $291.8M | $310.4M | $137.4M |
| Total current assets | $228.9M | $246.7M | $271.8M | $270.5M | $279.0M | $296.4M | $315.9M | $143.6M |
| Total current liabilities | $21.5M | $18.9M | $16.4M | $14.7M | $15.4M | $14.1M | $15.2M | $15.8M |
| Cash & equivalents | $112.5M | $124.2M | $103.8M | $71.0M | $58.8M | $70.8M | $136.6M | $66.6M |
| Marketable securities (current) | $112.9M | $119.0M | $165.2M | $194.4M | $215.7M | $221.8M | $175.8M | $72.4M |
| Other current assets | $132.0K | $181.0K | $168.0K | $208.0K | $970.0K | $997.0K | $981.0K | $1.6M |
| Marketable securities (non-current) | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $11.7M | $12.5M | $12.8M | $13.5M | $14.2M | $14.8M | $15.4M | $16.1M |
| Intangible assets | — | — | — | — | — | — | — | — |
| Other non-current assets | $1.1M | $1.1M | $1.0M | $1.1M | $1.1M | $896.0K | $975.0K | $789.0K |
| Accounts payable | $3.3M | $4.7M | $2.0M | $1.5M | $2.1M | $3.1M | $1.3M | $1.7M |
| Accrued liabilities | $15.2M | $11.1M | $10.8M | $9.4M | $9.1M | $6.8M | $9.7M | $10.4M |
| Other current liabilities | $1.1M | $947.0K | $564.0K | $327.0K | $359.0K | $745.0K | $342.0K | $523.0K |
| Other non-current liabilities | $0 | $0 | $51.0K | $51.0K | $51.0K | $51.0K | $51.0K | $51.0K |
| Common stock & paid-in capital | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Retained earnings | -$418.1M | -$383.6M | -$352.6M | -$327.9M | -$307.0M | -$284.9M | -$262.3M | -$242.8M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — | — | — | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$23.8M | -$26.1M | -$17.4M | -$19.5M | -$19.5M | -$20.8M | -$17.5M | -$15.6M |
| Investing cash flow | $6.1M | $46.2M | $29.6M | $22.0M | $7.5M | -$45.0M | -$102.6M | -$29.0M |
| Financing cash flow | $6.0M | $195.0K | $20.7M | $9.7M | $54.0K | $4.0K | $190.1M | $131.0K |
| Free cash flow | -$24.1M | -$26.4M | -$17.6M | -$19.6M | -$19.6M | -$21.6M | -$17.6M | -$15.7M |
| Capital expenditures | $354.0K | $281.0K | $128.0K | $127.0K | $148.0K | $780.0K | $116.0K | $167.0K |
| Depreciation & amortization | $813.0K | $847.0K | $1.5M | $800.0K | $754.0K | $749.0K | $2.4M | $800.0K |
| Share-based compensation | $7.9M | $3.6M | $3.4M | $3.4M | $3.4M | $4.0M | $2.5M | $2.5M |
| Change in accounts payable | -$1.1M | $2.4M | $409.0K | -$501.0K | -$975.0K | $1.7M | -$416.0K | -$29.0K |
| Purchases of investments | — | — | — | — | — | — | — | — |
| Sales/maturities of investments | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $0 | $925.0K | $0 | — | — |
| Operating income | -$103.3M | -$82.6M | -$55.6M | -$56.5M | -$60.7M |
| Net income | -$90.4M | -$75.1M | -$36.3M | -$55.2M | -$60.7M |
| EPS (diluted) | $-4.24 | $-4.28 | — | $-1.04 | $-1.10 |
| EPS (basic) | $-4.24 | $-4.28 | — | $-1.04 | $-1.10 |
| Operating margin | — | -$8.9K | — | — | — |
| Net margin | — | -$8.1K | — | — | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $288.6M | $335.7M | $222.6M | $109.3M | $163.3M |
| Total liabilities | $23.7M | $25.4M | $36.5M | $10.6M | $20.4M |
| Stockholders' equity | $264.9M | $310.4M | $186.0M | -$145.7M | -$91.9M |
| Total current assets | $271.8M | $315.9M | $200.3M | $84.7M | $144.0M |
| Total current liabilities | $16.4M | $15.2M | $23.0M | $6.7M | $8.6M |
| Cash & equivalents | $103.8M | $136.6M | $148.2M | $82.0M | $142.5M |
| Marketable securities (current) | $165.2M | $175.8M | $48.9M | $0 | $0 |
| Other current assets | $168.0K | $981.0K | $1.1M | $630.0K | $1.5M |
| Property, plant & equipment | $12.8M | $15.4M | $17.2M | $20.1M | — |
| Intangible assets | — | — | — | $0 | $128.0K |
| Other non-current assets | $1.0M | $975.0K | $764.0K | $0 | $1.9M |
| Accounts payable | $2.0M | $1.3M | $2.6M | $625.0K | — |
| Accrued liabilities | $10.8M | $9.7M | $17.5M | $5.3M | — |
| Other current liabilities | $564.0K | $342.0K | $737.0K | $167.0K | — |
| Other non-current liabilities | $51.0K | $51.0K | $203.0K | $0 | — |
| Common stock & paid-in capital | $0 | $0 | $0 | $0 | $0 |
| Retained earnings | -$352.6M | -$262.3M | -$187.2M | -$150.8M | -$393.5M |
| Accumulated other comprehensive income (loss) | — | — | — | -$21.0K | $0 |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$77.2M | -$70.6M | -$51.4M | -$52.8M | -$47.6M |
| Investing cash flow | $14.0M | -$125.3M | $25.6M | -$2.2M | -$3.3M |
| Financing cash flow | $30.4M | $184.1M | $92.5M | $66.5M | $732.0K |
| Free cash flow | -$78.4M | -$71.4M | -$51.7M | -$55.1M | -$50.8M |
| Capital expenditures | $1.2M | $808.0K | $321.0K | $2.2M | $3.3M |
| Depreciation & amortization | $3.0M | $3.2M | $3.3M | $3.2M | $1.3M |
| Share-based compensation | $14.2M | $8.3M | $1.4M | $1.3M | $11.6M |
| Change in accounts payable | $627.0K | -$77.0K | $667.0K | -$3.6M | — |
| Purchases of investments | — | — | — | $107.5M | $0 |
| Sales/maturities of investments | — | — | — | $49.5M | $0 |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding NGNE as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-02-20 to 2026-09-22
Recent transactions
- Insiders have net sold 19,200 shares over the last 182 days, across 0 purchases and 7 sales.
- Most recent: McMinn Rachel (Chief Executive Officer) — Option exercise of 756 shares on 2026-09-22.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)19,200 sh(7 txns)
Net Shares-19,200
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| McMinn Rachel | Chief Executive Officer | Option exercise | 2026-09-22 | 756 |
| Cvijic Christine Mikail | President and CFO | Open market sale | 2026-07-07 | 4,200 |
| Jordan Julie | Chief Medical Officer | Open market sale | 2026-03-26 | 828 |
| Cobb Stuart | Chief Scientific Officer | Open market sale | 2026-03-13 | 3,991 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-22 | McMinn Rachel | Chief Executive Officer | Option exercise | 756 | $25.32 |
| 2026-07-07 | Cvijic Christine Mikail | President and CFO | Open market sale | 4,200 | $36.13 |
| 2026-07-06 | Cvijic Christine Mikail | President and CFO | Open market sale | 600 | $36.02 |
| 2026-07-02 | Cvijic Christine Mikail | President and CFO | Open market sale | 2,531 | $34.58 |
| 2026-07-02 | Cvijic Christine Mikail | President and CFO | Open market sale | 1,530 | $35.23 |
| 2026-07-01 | Cvijic Christine Mikail | President and CFO | Open market sale | 739 | $34.06 |
| 2026-05-06 | Cvijic Christine Mikail | President and CFO | Open market sale | 4,800 | $30.07 |
| 2026-05-06 | Cvijic Christine Mikail | President and CFO | Open market sale | 4,800 | $32.44 |
| 2026-03-26 | Cvijic Christine Mikail | President and CFO | Open market sale | 2,558 | $21.62 |
| 2026-03-26 | McMinn Rachel | Chief Executive Officer | Open market sale | 3,352 | $22.07 |
| 2026-03-26 | Jordan Julie | Chief Medical Officer | Open market sale | 828 | $21.89 |
| 2026-03-13 | Cobb Stuart | Chief Scientific Officer | Open market sale | 3,991 | $20.41 |
| 2026-03-13 | Cobb Stuart | Chief Scientific Officer | Open market sale | 2,658 | $21.34 |
| 2026-03-13 | Cobb Stuart | Chief Scientific Officer | Open market sale | 148 | $22.08 |
| 2026-03-13 | Cvijic Christine Mikail | President and CFO | Open market sale | 2,387 | $20.42 |
| 2026-03-13 | Cvijic Christine Mikail | President and CFO | Open market sale | 1,395 | $21.25 |
| 2026-03-13 | Cvijic Christine Mikail | President and CFO | Open market sale | 263 | $22.02 |
| 2026-02-27 | Cvijic Christine Mikail | President and CFO | Open market sale | 4,800 | $25.11 |
| 2026-02-20 | Cobb Stuart | Chief Scientific Officer | Grant / award | 16,500 | $0.00 |
| 2026-02-20 | Jordan Julie | Chief Medical Officer | Grant / award | 4,900 | $0.00 |
| 2026-02-20 | Cvijic Christine Mikail | President and CFO | Grant / award | 22,000 | $0.00 |
| 2026-02-20 | McMinn Rachel | Chief Executive Officer | Grant / award | 25,900 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 06:49 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-02 | 4 | 2026-09-22 | View on SEC.gov → |
| 2026-08-11 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-11 | 8-K | 2026-08-11 | View on SEC.gov → |
| 2026-07-07 | 4 | 2026-07-06 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-07-02 | 8-K | 2026-06-30 | View on SEC.gov → |
| 2026-06-29 | 8-K | 2026-06-29 | View on SEC.gov → |
| 2026-06-08 | 8-K | 2026-06-08 | View on SEC.gov → |
| 2026-06-04 | 8-K | 2026-06-03 | View on SEC.gov → |
| 2026-05-12 | 8-K | 2026-05-12 | View on SEC.gov → |
| 2026-05-12 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-08 | 4 | 2026-05-06 | View on SEC.gov → |
Recent news
Headlines about NGNE (Neurogene Inc.). Links open the publisher — we don’t host full articles.
-
NGNE Nov 2026 20.000 put (NGNE261120P00020000) Interactive Stock Chart - Yahoo Finance
Yahoo! Finance Canada · 2026-10-21 -
NGNE Nov 2026 20.000 put (NGNE261120P00020000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-21 -
Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress
Yahoo · 2026-10-20 -
Trading Systems Reacting to (NGNE) Volatility
Stock Traders Daily · 2026-10-16 -
NGNE Oct 2026 50.000 call (NGNE261016C00050000) interactive stock chart
Yahoo Finance UK · 2026-10-16 -
NGNE Oct 2026 50.000 call (NGNE261016C00050000) stock price, news, quote and history
Yahoo Finance UK · 2026-10-16 -
Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?
Yahoo · 2026-10-13 -
Neurogene is a new Overweight at J.P. Morgan on Rett syndrome therapy
Seeking Alpha · 2026-10-08
No headlines in this category right now — try “All”.